These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24368428)

  • 1. Effectiveness of a multi-component Smoking Cessation Support Programme (McSCSP) for patients with severe mental disorders: study design.
    Garcia-Portilla MP; Garcia-Alvarez L; Saiz PA; Diaz-Mesa E; Galvan G; Sarramea F; Garcia-Blanco J; Elizagarate E; Bobes J
    Int J Environ Res Public Health; 2013 Dec; 11(1):373-89. PubMed ID: 24368428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatments for smoking cessation.
    Cahill K; Stevens S; Lancaster T
    JAMA; 2014 Jan; 311(2):193-4. PubMed ID: 24399558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents.
    Bailey SR; Crew EE; Riske EC; Ammerman S; Robinson TN; Killen JD
    Paediatr Drugs; 2012 Apr; 14(2):91-108. PubMed ID: 22248234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varenicline in the management of smoking cessation: a single technology appraisal.
    Hind D; Tappenden P; Peters J; Kenjegalieva K
    Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD; Dugan SE
    Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline.
    Johnson TS
    J Am Acad Nurse Pract; 2010 Oct; 22(10):557-63. PubMed ID: 21040090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy for smoking cessation in schizophrenia: a systematic review.
    Kozak K; George TP
    Expert Opin Pharmacother; 2020 Apr; 21(5):581-590. PubMed ID: 32011186
    [No Abstract]   [Full Text] [Related]  

  • 12. A preliminary benefit-risk assessment of varenicline in smoking cessation.
    Cahill K; Stead L; Lancaster T
    Drug Saf; 2009; 32(2):119-35. PubMed ID: 19236119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta-analysis, and network meta-analysis.
    Siskind DJ; Wu BT; Wong TT; Firth J; Kisely S
    Lancet Psychiatry; 2020 Sep; 7(9):762-774. PubMed ID: 32828166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smoking cessation in severe mental ill health: what works? an updated systematic review and meta-analysis.
    Peckham E; Brabyn S; Cook L; Tew G; Gilbody S
    BMC Psychiatry; 2017 Jul; 17(1):252. PubMed ID: 28705244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
    Annemans L; Nackaerts K; Bartsch P; Prignot J; Marbaix S
    Clin Drug Investig; 2009; 29(10):655-65. PubMed ID: 19715382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
    JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Varenicline and combination nicotine replacement therapy are the most effective pharmacotherapies for treating tobacco use.
    Ebbert JO
    Evid Based Med; 2013 Dec; 18(6):212-3. PubMed ID: 24030984
    [No Abstract]   [Full Text] [Related]  

  • 19. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
    Tonstad S
    J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
    Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
    JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.